Chester County News and Community Website
WEST CHESTER, PA — Molecular Targeting Technologies Inc. (MTTI) will present clinical data from 81 patients at the 5th Targeted Radiopharmaceuticals Summit, offering evidence that its Evans Blue drug delivery …
MTTI to Present 81-Patient Radiopharma Data at Oncology Summit Read More
WILMINGTON, DE — AstraZeneca and YMCA of the USA formed a five-year partnership to expand cancer screening education, early detection awareness and survivorship support, aiming to reach 175,000 people in …
AstraZeneca, YMCA Target Cancer Screening Gap in Five-Year Push Read More
PLYMOUTH MEETING, PA — Patients with advanced cancer were significantly more likely to discuss and document their care preferences when both they and their physicians received targeted reminders, according to …
Cancer Care Study Finds Targeted Prompts Increase End-of-Life Discussions Read More WILMINGTON, DE — AstraZeneca reported updated Phase III trial results showing its investigational breast cancer therapy camizestrant extended the time patients lived without disease progression and delayed the need for …
AstraZeneca Breast Cancer Drug Extends Progression-Free Survival Read More PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network has launched a free weekly email service that alerts users to changes in its widely used cancer treatment guidelines, expanding access …
NCCN Launches Weekly Cancer Guideline Alerts for Clinicians Read More
WILMINGTON, DE — AstraZeneca and Daiichi Sankyo have secured U.S. approval for DATROWAY as a first-line treatment for certain patients with metastatic triple-negative breast cancer, expanding treatment options in a …
AstraZeneca, Daiichi Sankyo Win FDA Approval for DATROWAY in Breast Cancer Read More PLYMOUTH MEETING, PA — A new analysis of clinical trial data found that methylphenidate-based stimulants may provide measurable relief for cancer-related fatigue, adding evidence for a treatment approach oncologists have …
Study Finds ADHD Drugs May Ease Cancer Fatigue Symptoms Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved Bizengri for adults with advanced NRG1 fusion-positive cholangiocarcinoma, marking the first approved treatment for the rare bile duct cancer …
FDA Approves Bizengri for Rare Bile Duct Cancer Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported additional Phase 2 trial data showing a dose-response relationship for its SkinJect treatment candidate for nodular basal cell carcinoma, with the …
Medicus Pharma Reports Expanded Phase 2 Skin Cancer Trial Data Read More PLYMOUTH MEETING, PA — National Comprehensive Cancer Network released a new patient guide on prostate cancer screening aimed at explaining current screening recommendations and addressing concerns about testing and treatment.
NCCN Releases Patient Guide on Prostate Cancer Screening Read More